LEVODOPA/BENSERAZIDE TEVA 200 mg/50 mg, hard capsule 60 capsules
Active ingredients: Benserazide, Benserazide hydrochloride, LÉVODOPA
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LEVODOPA/BENSERAZIDE TEVA 200 mg/50 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) de 60 gélule(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 8 Dec 2009
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60660790CIP73832959CIP133400938329599Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVODOPAgélule | 200,00 mg · une gélule | SA |
| CHLORHYDRATE DE BENSÉRAZIDEgélule | — | SA |
| BENSÉRAZIDE BASEgélule | 50,00 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.